About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
- WOMEN
- 2026 Readers' Choice Awards
Classifieds
Weather
Obituaries

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

215.87 -5.69 (-2.57%)

Streaming Delayed Price Updated: 2:42 PM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

61 62 Next >

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab ↗

March 22, 2024

Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.

Via Benzinga

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 21, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 20, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 19, 2024

Via Benzinga

A Closer Look at 21 Analyst Recommendations For Biogen ↗

March 05, 2024

Via Benzinga

Biogen Unusual Options Activity ↗

February 29, 2024

Via Benzinga

10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? ↗

March 16, 2024

Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...

Via Talk Markets

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 14, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers ↗

March 08, 2024

February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks...

Via Benzinga

Topics Economy

Peering Into Biogen's Recent Short Interest ↗

February 19, 2024

Via Benzinga

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision ↗

March 08, 2024

The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA...

Via Benzinga

FDA Delays Decision On Eli Lilly's Alzheimer Drug ↗

March 08, 2024

The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab.

Via Investor's Business Daily

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗

March 06, 2024

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...

Via Benzinga

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 06, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

March 04, 2024

From Biogen Inc.

Via GlobeNewswire

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223? ↗

March 02, 2024

Getting its Alzheimer's medicine approved in the European Union could be big.

Via The Motley Fool

Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) ↗

February 29, 2024

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

Via Benzinga

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm

February 24, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

February 23, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

February 23, 2024

From Biogen Inc.

Via GlobeNewswire

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗

February 22, 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

Via InvestorPlace

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

February 22, 2024

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

February 21, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024 ↗

February 19, 2024

Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.

Via InvestorPlace

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Via InvestorPlace

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says ↗

February 14, 2024

Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.

Via Benzinga

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 14, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Biogen (BIIB) Q4 2023 Earnings Call Transcript ↗

February 13, 2024

BIIB earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Sections

Services

Contact Information

Follow Us